• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Light Therapy Work for Non-Seasonal Depression?

Does Light Therapy Work for Non-Seasonal Depression?

April 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
bret-a-moore-psyd-abppBret A. Moore, PsyD, ABPP Board-Certified Clinical Psychologist, San Antonio, TX Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
(Lam R et al, JAMA Psychiatry 2016;73(1):56-63)

Many studies have shown that light therapy works for seasonal affective disorder, but does it work for non-seasonal major depression? That’s less clear. Systematic reviews have yielded inconclusive results, in part because prior studies have had methodological weaknesses. A new study with a robust design was just published.

Over a 5-year period, researchers recruited 122 adult patients with non-seasonal major depression between the ages of 19 through 60 from three clinics in Canada. The patients were randomized to 1 of 4 groups: light therapy alone, fluoxetine 20 mg plus light therapy (combination treatment), fluoxetine 20 mg plus sham negative ion treatment, and double placebo (placebo pills plus negative ion). Light therapy was given with a 10,000-lux fluorescent light box for 30 minutes daily in the early morning. The study lasted 8 weeks, and 106 participants completed it. The primary outcome measure was change in the Montgomery-Åsberg Depression Rating Scale (MADRS); secondary outcomes included response and remission rates.

At study conclusion, both light therapy and combination therapy were superior to placebo; however, combination therapy beat placebo more consistently. Whereas light therapy yielded lower MADRS scores than placebo, combination therapy bested placebo on MADRS scores, response rates, and remission rates. Surprisingly, fluoxetine was not significantly better than placebo; the authors attribute this to small sample size.

Here are the numbers: Average improvements in MADRS scores were 16.9 (combined fluoxetine and light), 13.4 (light), 8.8 (fluoxetine and sham light), and 6.5 (placebo). Response rates (defined as ≥ 50% drop in MADRS score) for combined treatment, light, fluoxetine, and placebo were 76%, 50%, 29% and 33%, respectively. Remission rates (defined as MADRS score ≤ 10) were 59%, 44%, 19% and 30%.

TCPR’s Take
This is probably the best designed clinical trial of light therapy for non-seasonal depression to date, and the results endorse both light monotherapy and combination light and fluoxetine, with the combination being possibly more robust. The bottom line is that, at least for depressed patients in the higher latitudes, you should consider recommending light therapy either alone or in combination with SSRIs.
General Psychiatry
KEYWORDS depressive_disorder research-update seasonal_affective_disorder
Bret a moore psyd abpp
Bret A. Moore, PsyD, ABPP

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

More from this author
www.thecarlatreport.com
Issue Date: April 1, 2016
SUBSCRIBE NOW
Table Of Contents
Take The CME Post-Test for Antidepressant Roundup, TCPR, November/December 2016
Does Light Therapy Work for Non-Seasonal Depression?
Thinking Creatively About Treatment-Resistant Depression
Four Newer Antidepressants: Should You Use Them?
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.